CSL, Calimmune lock $91m deal
“Calimmune shares in our promise and focus to improve the lives of patients with rare and serious medical conditions,” said CSL Limited CEO and managing director, Paul Perreault.
“Calimmune’s scientific accomplishments are impressive. The team has built a robust technology platform, and designed a promising HSC gene therapy candidate – CAL-H, which strongly aligns with our longer-term strategic goals, and complements our core competencies and areas of therapeutic focus.”
The acquisition will provide CSL Behring, one of the company’s core businesses, with Calimmune’s haematopoietic stem cell gene therapy. The therapy aims to treat inherited disorders that affect haemoglobin.
“We are excited to become part of CSL Behring. They are an established global industry leader in protein-replacement therapies and have a proven track record of driving innovations through the development pipeline and delivering differentiated products to the global marketplace. Together, we are well positioned to take our achievements to the next level,” commented Calimmune CEO Louis Breton.
The acquisition includes medical facilities in Pasadena, California and Sydney. It also involves two proprietary platform technologies designed to address some major challenges with the commercialisation of stem cell therapy. according to AAP.